TELO

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is a pre-clinical stage biotechnology company founded in 2021 and headquartered in Baltimore, Maryland. The company was formerly known as Metallo Therapies Inc. before changing its name in October 2022. Telomir went public in April 2019 and focuses on developing therapeutic treatments targeting human stem cells and age-related inflammatory conditions. As a pre-clinical company, Telomir has not yet generated revenue and is currently in the research and development phase of bringing its lead drug candidate to market.